Medication leaflets

Active substance

Results for the substance emicizumab

5 results

About this active substance

Emicizumab is an antibody used to prevent bleeding in haemophilia A in patients selected by a haematologist, with or without factor VIII inhibitors. It functionally replaces part of factor VIII's role in clotting. It does not cure haemophilia and is not a treatment for haemophilia B.

It is injected under the skin, not into a vein. After initial weekly doses, maintenance may be weekly, every two weeks or every four weeks, as prescribed. Home administration is possible after training. It does not treat a bleed already in progress: follow the haemophilia centre's plan for bleeding and procedures.

Common effects include injection-site redness or pain, headache and joint pain. Combined use with activated prothrombin complex concentrate (aPCC) can cause blood clots and damage to small blood vessels, especially with large or repeated doses. Do not add medicines to control bleeding without the haematologist's instructions.

Tell every doctor and laboratory that you use emicizumab. It affects some coagulation tests, including aPTT, so results may be misleading. Carry the patient alert card. Seek urgent help for chest pain, breathlessness, a painful swollen leg, neurological symptoms or reduced urination. Also report any increase in the frequency of bleeding.